Tau's mitochondrial twist fuels new Alzheimer's drug strategy

TL;DR Summary
Stanford researchers found tau can trigger reverse electron transport in mitochondria, generating reactive oxygen species and cellular stress; blocking this retrograde flow reversed harmful effects and improved learning/memory in flies and mice, suggesting a novel therapeutic angle for Alzheimer’s. Early human cell/tissue data support the idea, and two authors have started a biotech startup to pursue further validation, though results in people remain unproven.
- Study reveals new role for tau, a top target for Alzheimer’s drug development STAT
- Atomic view of Alzheimer's disease peptide could inform new drugs Phys.org
- How Tau is transforming the future of Alzheimer’s diagnosis and treatment News-Medical
- Physician Views Results: Doctors see diranersen bolstering tau — as a partner, not a solo act FirstWord Pharma
- Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store BioSpace
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
2 min
vs 3 min read
Condensed
87%
490 → 64 words
Want the full story? Read the original article
Read on STAT